Hyperfine, Inc. (HYPR) Stock: Price, Forecast & Analyst Target
Hyperfine, Inc. (HYPR) — MoonshotScore 21/100 (Weak band), calculated Nov 18, 2026. Price $0.5449 (-2.97%), as of the Nov 18, 2026 trading session; market cap $57.8M.
Educational signal · not a buy or sell recommendation · How to read this
Hyperfine, Inc. · HYPR · NASDAQ
Hyperfine, Inc. specializes in portable magnetic resonance imaging, offering the Swoop system for point-of-care medical imaging. The company aims to address unmet needs in medical imaging through innovative hardware and software solutions.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Hyperfine (HYPR)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Durable growth, but bottom-tier quality, a fragile balance sheet and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Poor; Financial Safety: Strained; Valuation: Rich; Growth Durability: Growing; Momentum: Slipping.
- quarterly revenue $3M (Q3 FY2025, quarter ended Sep 2025)
- EPS beat 2 of the last 8 reports
- Altman Z -7.81 · Piotroski F 4
Holding back: weak fundamentals, balance-sheet strain, weak price trend
Helping: durable growth
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 20 | Weak | |
| 21 | Weak | |
| 21 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.5449 | |
| Change on the day | -2.97% | |
| 52-week range | $0.5426 – $1.94 | |
| Market capitalisation | $57.8M | — |
| Shares traded on the day | 940.9K |
Price & events
Other perspectives
Council score for Hyperfine (HYPR): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
4 lenses, 4 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
Two of these lenses read this company more favourably than the MoonshotScore does: Griffin-style lens and Englander-style lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Hyperfine (HYPR), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Hyperfine, Inc. (HYPR) is listed on NASDAQ. It employs 102 people and is led by Maria Degois Sainz. In Q3 FY2025 it reported revenue of $3M and net income of -$11M. The market values it at $57.8M.
What do the latest results show for Hyperfine (HYPR)?
Short answer · as of
The most recent reported quarter, Q3 FY2025, carried revenue of $3M. Against analyst estimates the company has EPS beat 2 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2025 | $3M | -$11M | -$0.14 (diluted) |
| Q4 FY2025 | $5M | -$6M | -$0.06 (diluted) |
| Q1 FY2026 | $4M | -$9M | -$0.09 (diluted) |
| Q2 FY2026 | $4M | -$9M | -$0.09 (diluted) |
What are the financial strengths and risks for Hyperfine (HYPR)?
Short answer · as of
The MoonshotScore pillars rate durable growth as strengths. What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -7.81 · Piotroski F 4. Trailing ratios: ROE -82.9% · ROA -51.6% · current ratio 5.10 · earnings yield -46.1% · free-cash-flow yield -50.3%.
Data-derived red flags
- Listing risk — at $0.5449 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -7.81 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-82.9%) — the business is not currently generating profit on shareholder capital.
What should you watch next at Hyperfine (HYPR)?
Short answer · as of
Current published price targets run low $2.00 · high $2.00 · consensus $2.00 · median $2.00 against a quoted price of $0.5449 (as of Nov 18, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
- No insider Form 4 transaction falls inside the window this page reads.
- The newest quarter held here (Q3 FY2025) was filed Nov 13, 2025 — 12 months ago.
Checked against the records this page reads, on the dates shown above.
How does Hyperfine compare with its peers?
Short answer
Hyperfine's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $8.78 Nov 18, 2026 | $333M | 88 5-pillar Nov 18, 2026 | |
| $23.40 Nov 18, 2026 | $191M | 87 5-pillar Nov 18, 2026 | |
| $8.98 Nov 18, 2026 | $361M | 87 5-pillar Nov 18, 2026 | |
| $13.62 Nov 18, 2026 | $182M | 71 5-pillar Nov 18, 2026 | |
| $328.10 Nov 18, 2026 | $339B | 68 5-pillar Nov 18, 2026 | |
| $4.85 Nov 18, 2026 | $59.6M | 44 5-pillar Nov 18, 2026 | |
| $1.63 Nov 18, 2026 | $103M | 43 5-pillar Nov 18, 2026 | |
| $3.67 Nov 18, 2026 | $110M | 41 5-pillar Nov 18, 2026 | |
| $2.38 Nov 18, 2026 | $36.2M | 39 5-pillar Nov 18, 2026 | |
| $5.57 Nov 18, 2026 | $145M | 37 5-pillar Nov 18, 2026 | |
| $6.61 Nov 18, 2026 | $269M | 36 5-pillar Nov 18, 2026 | |
| $9.52 Nov 18, 2026 | $396M | 35 5-pillar Nov 18, 2026 | |
| Hyperfine (HYPR) — this page | $0.5449 | $57.8M | 21 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $2.00 – $2.00
- Consensus target
- $2.00
- Median target
- $2.00
Consensus record · Captured .
Measured against a quoted price of $0.5449 (as of Nov 18, 2026).
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held HYPR in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported HYPR in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What Investors Ask About Hyperfine (HYPR)
These answers are editorial: 1 of these 9 answers is drawn from the HYPR research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for HYPR?
HYPR carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Hyperfine, Inc. specializes in portable magnetic resonance imaging, offering the Swoop system for point-of-care medical imaging.
Is HYPR a good stock to buy?
Stock Expert AI does not rate HYPR buy, sell or hold. Hyperfine, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the HYPR stock price today?
The last price recorded for Hyperfine, Inc. (HYPR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the HYPR price target?
The analyst consensus price target for Hyperfine, Inc. (HYPR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What do analysts say about HYPR stock?
Analyst coverage of Hyperfine, Inc. (HYPR) focuses on the company's growth potential in the point-of-care medical imaging market. Key valuation metrics include market capitalization and revenue growth.
What are the key factors to evaluate for HYPR?
Hyperfine, Inc. (HYPR) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Focus on point-of-care medical imaging with the Swoop Portable MR imaging system. Not financial advice.
How frequently does HYPR data refresh on this page?
HYPR's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven HYPR's recent stock price performance?
Hyperfine, Inc. (HYPR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative Swoop Portable MR Imaging System. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider HYPR overvalued or undervalued right now?
Hyperfine, Inc. (HYPR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 19 figures on this page — 11 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com